Thrombotic complications with SARS-CoV-2 infection in patients with cancer on high-risk therapies: Data from the COVID-19 and Cancer Consortium (CCC19).

• DOI: 10.1200/jco.2021.39.15_suppl.e18788
• Publication Date: 2021-06-02T14:28:38Z
• Authors: Shuchi Gulati; Surbhi Shah; Amit Kulkarni; Aakash Desai; Julie Fu; Rebecca Zon; Vaibhav Kumar; Chih-Yuan Hsu; Clara Hwang; Deborah Blythe Do...; Imo Akpan; Jennifer Girard; Peter Paul Yu; Rana R. McKay; Ziad Bakouny; Jean Connors; Dimpy P. Shah; Jeremy Lyle Warner; Rachel Pam Greene...; Petros Grivas
• Keywords: Clinical endpoint

e18788 Background: Patients (pts) with cancer have a high risk of venous thromboembolic (VTE) complications, further enhanced by anti-cancer treatments, specifically hormonal therapies, targeted therapies (VEGF inhibitors, other TKIs) and immune checkpoint inhibitors (ICIs). We hypothesized that high-risk would predispose pts COVID-19 to higher VTE complications. Methods: CCC19 is the largest international registry (NCT04354701) recording outcomes COVID-19. The was queried for hospitalized who developed received systemic treatment in year prior Incidence analyzed as primary endpoint; 30-day any cause mortality & need ICU admission at baseline were secondary endpoints without respectively. Pts stratified type time from last dose: <2 wk, 2-4 1-3 months (mos), 3-12 mos. Results: As February 9th 2021, 4217 complications data present registry. 1867 (44%) had therapy within analyzed. There total 186 (10%) events. Of these, incidence 141 (10.5%) solid tumors 57 (9%) hematologic malignancies. Overall 20% 22% respectively, while direct presentation seen 17% 10% VTE, Treatment timing drug exposures are below (Table). Receipt 3 mos vs associated increased rate OR 2.44, 95% CI 1.18-5.84, p=0.011 (univariate Fisher test). Conclusions: describe events recent therapy. ICI VEGFi numerically rates VTE; examined drugs classes not. Timing appears modify VTE. Although retrospective, possible selection confounding biases, our analysis suggests factors than may drive this population.[Table: see text]